EW · Edwards Lifesciences Corporatio
$90.56
+1.67% last session
End-of-day data · close of 2026-10-26
Market cap
$52B
Enterprise value
$49B
Trailing P/E
53.9
Forward P/E
26.8
Dividend yield
0.0%
Beta
0.86
Avg volume
3M
Employees
16K
Daily Change %
1.67%
5 Days Change
0.52%
10 Days Change
4.57%
30 Days Change
4.95%
60 Days Change
0.39%
Month to Day Change
6.30%
Year to Day Change
6.23%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — EW
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-07
Latest call per bank · past 12 months
Barclays
Overweight$110
+21.5% vs priceJP Morgan
Overweight$105
+15.9% vs priceRBC Capital
Outperform$110
+21.5% vs priceCitigroup
Buy$110
+21.5% vs priceGoldman Sachs
Buy$95.00
+4.9% vs priceWells Fargo
Overweight$100
+10.4% vs priceUBS
Neutral$95.00
+4.9% vs priceJefferies
Buy$98.00
+8.2% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-07 | Barclays | Initiates | Overweight | $0.00 → $110 |
| 2026-09-11 | BTIG | Reiterates | Buy | $110 |
| 2026-07-25 | Leerink Partners | Upgrade | Market Perform → Outperform | $87.00 → $101 |
| 2026-07-24 | JP Morgan | Maintains | Overweight | $100 → $105 |
| 2026-07-24 | Piper Sandler | Reiterates | Overweight | $100 → $101 |
| 2026-07-16 | Truist Securities | Maintains | Hold | $90.00 → $95.00 |
| 2026-07-15 | Mizuho | Maintains | Outperform | $100 → $105 |
| 2026-07-13 | RBC Capital | Maintains | Outperform | $100 → $110 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-26
- neutral: RSI (14): RSI is 60 — neutral momentum, neither overbought nor oversold.
- bullish: Price vs 50-day MA: Trading 2.9% above the 50-day MA ($88.04).
- bullish: Price vs 200-day MA: Trading 6.2% above the 200-day MA ($85.26).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.55) — short-term momentum is improving.
- bullish: 52-week range: Price is within 5% of the 52-week high ($95.18).
EW Price Chart
Loading chart for EW…
Fundamentals
About Edwards Lifesciences Corporatio
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
More in Medical Devices
ABT
Abbott Laboratories
$181B -14.2% YTD
MDT
Medtronic plc.
$121B 1.2% YTD
SYK
Stryker Corporation
$117B -12.2% YTD
BSX
Boston Scientific Corporation
$66B -52.2% YTD
GEHC
GE HealthCare Technologies Inc.
$33B -12.1% YTD
DXCM
DexCom, Inc.
$30B 18.4% YTD
PHG
Koninklijke Philips N.V. NY Reg
$26B 1.9% YTD
STE
STERIS plc (Ireland)
$22B -8.5% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.